Genetics of melanoma chemoresistance

ScienceDaily (June 5, 2011) — Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a paper published in Genes Development, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile (“secretome”) that can ultimately promote metastasis and contribute to melanoma relapse. While cellular senescence has been thought … Continue reading “Genetics of melanoma chemoresistance”

ScienceDaily (June 5, 2011) — Malignant melanoma is a highly aggressive and notoriously chemoresistant form of cancer. In a paper published in Genes Development, Ohanna et al. reveal that anti-melanoma drugs may, paradoxically, induce a senescence-associated secretory profile (“secretome”) that can ultimately promote metastasis and contribute to melanoma relapse.

While cellular senescence has been thought of as a natural mechanism to combat uncontrolled cell growth, or cancer, recent studies have shown that some cell types express a secretome during senescence that alters the tumor microenvironment and affects the cell’s response to chemotherapeutic drugs. Ohanna et al. confirm that senescent melanoma cells do, in fact, express an inflammatory secretome, and have delineated the genetic pathways involved: Depletion of the MITF transcription factor, or exposure to anti-melanoma drugs, activates the DNA damage response and triggers senescence. Senescent melanoma cells express a PARP-1 and NF-kB — associated secretome, which contains high levels of the chemokine CCL2. CCL2, in turn, leads to a loss of E-cadherin expression and an invasive phenotype.

In fact, Ohanna et al. show that culturing melanoma cells with exogenous CCL2 enhances their survival and invasiveness. This finding suggests that blocking CCL2, or its upstream effectors, may represent a novel therapeutic pathway.

As Dr. Bertolotto explains, “Our data disclose a part of the mechanisms contributory to failure of anti-melanoma chemotherapies and we gain valuable insight for the identification of new candidates, namely PARP-1, NF-kB or CCL2, for therapeutic intervention in view to overcome drug resistance.”


Story Source:

The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by Cold Spring Harbor Laboratory, via EurekAlert!, a service of AAAS.


Journal Reference:

  1. Mickael Ohanna, Sandy Giuliano, Caroline Bonet, Veronique Imbert, Veronique Hofman, Josephine Zangari, Karine Bille, Caroline Robert, Brigitte Bressac-de Paillerets, Paul Hofman, Stephane Rocchi, Jean-Francois Peyron, Jean-Philippe Lacour, Robert Ballotti and Corine Bertolotto. Senescent cells develop a PARP-1 and Nuclear Factor-kappa B-associated secretome (PNAS). Genes Development, 2011; 25 (12) [link]

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply